Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (48)

2023

  1. C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer's disease targeting tauopathies

    European Journal of Medicinal Chemistry, Vol. 251

  2. Non-Excitatory Amino Acids, Melatonin, and Free Radicals: Examining the Role in Stroke and Aging

    Antioxidants, Vol. 12, Núm. 10

  3. Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

    Pharmaceutics, Vol. 15, Núm. 6

2022

  1. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2021

  1. In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral N-Propargyl-1,2-amino Alcohol Derivatives

    Chemical Research in Toxicology, Vol. 34, Núm. 5, pp. 1245-1249

  2. The coronavirus disease 2019 (Covid-19): Key emphasis on melatonin safety and therapeutic efficacy

    Antioxidants, Vol. 10, Núm. 7

2020

  1. Cerebral ischemia and traumatic brain injury: Protection by melatonin

    Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 231-255

  2. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  3. Melatonin reduces NLRP3 inflammasome activation by increasing α7 nAChR-mediated autophagic flux

    Antioxidants, Vol. 9, Núm. 12, pp. 1-18

  4. Melatonin's efficacy in stroke patients; a matter of dose? A systematic review

    Toxicology and Applied Pharmacology, Vol. 392

2019

  1. Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics

    Cancers, Vol. 11, Núm. 11

  2. Quinoxalinetacrine QT78, a cholinesterase inhibitor as a potential ligand for Alzheimer’s disease therapy

    Molecules, Vol. 24, Núm. 8

  3. The emergence of melatonin in oncology: Focus on colorectal cancer

    Medicinal Research Reviews, Vol. 39, Núm. 6, pp. 2239-2285

2018

  1. How melatonin combats ischemic brain injury

    Melatonin: Medical Uses and Role in Health and Disease (Nova Science Publishers, Inc.), pp. 185-209

  2. Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases

    British Journal of Pharmacology, Vol. 175, Núm. 16, pp. 3220-3229

2017

  1. Ischemic brain injury: New insights on the protective role of melatonin

    Free Radical Biology and Medicine, Vol. 104, pp. 32-53

  2. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 765-780

  3. Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®)

    CNS Neuroscience and Therapeutics

2016

  1. Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices

    NeuroToxicology, Vol. 57, pp. 61-68

  2. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973